Solvemed is a VC-backed Neuroscience AI company working to redefine neurology care and drug development. With neurodegenerative diseases (dementias) as the primary focus area, Solvemed leverages its proprietary machine learning technology to develop first-in-class digital biomarkers to support development of neurological drugs and establish affordable clinical examination and remote monitoring tools. Our products enable better care and improved treatment outcomes for neurology patients and have the potential to benefit healthcare systems by optimising clinical pathways. Through our proprietary medical data repositories and innovative analytics, we help our biopharmaceutical industry partners drive clinical trial efficiency and make first-in-class disease-modifying drugs possible. Everything we do is strongly embedded in world-class science. Our global team of renowned scientists and technology experts works closely with clinical researchers from top research institutions, such as University College London Hospital, Barts Health NHS Trust, and Harvard Medical School, among other.